|
Broadly neutralizing human mAbs targeting the SARS‑CoV‑2 spike protein
Problem
Monoclonal antibodies (mAbs) that target the SARS-CoV-2 spike protein have been shown to have clinical benefits in the treatment of SARS-CoV-2 infection. The activity of anti-SARS-CoV-2 mAbs against specific variants and subvariants of this virus can vary dramatically. There is a clinical need for continued identification of anti-SARS-CoV-2...
|
